Bihua Chen
Executive Chairperson & CEOMs. Bihua Chen is Executive Chairperson and Chief Executive Officer of Helix Acquisition Corp. III since September 2025 and has served as an Independent Director of BlossomHill Therapeutics, Inc. since February 2021. Ms. Chen is the founder of Cormorant Asset Management, LP, an investment firm focused on innovative biotechnology, medical technology and life science companies and has managed Cormorant's hedge fund as well as its private equity funds since its founding in February 2013. Prior to founding Cormorant, from 2005 to 2010, Ms. Chen served as a sub-adviser to Millennium Management LLC, a multi-strategy hedge fund. Previously, from 2001 to 2002, Ms. Chen was a healthcare analyst and sector portfolio manager for investment advisor American Express Asset Management. Ms. Chen also served as a portfolio manager for the Asterion Life Science Fund from 2001 to 2002, an equity analyst and portfolio manager for Bellevue Research from 2000 to 2001 and an equity analyst for Putnam Investments from 1998 to 2001. Ms. Chen has served on the board of directors of Helix Acquisition Corp III, a publicly traded biotechnology special purpose acquisition company, since January 2026 and BridgeBio Oncology Therapeutics, Inc. since August 2025. Ms. Chen served on the board of directors of Biomea Fusion, Inc. from December 2020 to July 2025, Erasca, Inc. from March 2021 to August 2023, Helix Acquisition Corp II, a publicly traded biotechnology special purpose acquisition company that entered into a business combination with BridgeBio Oncology Therapeutics in August 2025, from January 2024 to August 2025 and Atea Pharmaceuticals, Inc. from June 2018 through October 2020. Ms. Chen was also the Chief Executive Officer and Chairperson of Helix Acquisition Corp. II from its inception until August 2025. From August 2020 to April 2022, Ms. Chen served as the Chief Executive Officer and Chairman of the board of directors of Helix Acquisition Corp., a publicly traded biotechnology special purpose acquisition company that entered into a business combination with MoonLake Immunotherapeutics AG in April 2022. Ms. Chen is currently a Board Member of Adona Medical, Inc., Akura Medical, Inc., Aleksia Therapeutics, Inc., Atia Vision, Inc., Averto Medical, BiVACOR, Inc., Element Science, Inc., Graviton Bioscience, Interius BioTherapeutics, Myra Vision, Inc., nChroma Bio, Nexo Therapeutics, Inc., Obvius Robotics, Orionis Biosciences, Supira Medical, Tiger Biotherapeutics, Tioga Cardiovascular and Tupos Therapeutics Inc. Ms. Chen received her B.S. in genetics and genetic engineering from Fudan University, Shanghai, China, in 1990, her M.S. in molecular biology from the Weill Cornell Graduate School of Medical Sciences in 1994 and her MBA from the Wharton School of the University of Pennsylvania in 1998.
Positions
- Company NameHelix Acquisition Corp. IIIStock CodeHLXCPositionExecutive Chairperson & CEO
- Company NameBlossomHill Therapeutics, Inc.Stock CodeBLSMPositionIndependent DirectorColleagues
- YLYishan LiCo-Founder & Executive Chairman
- JJJingrong Jean CuiScientific Founder, President, CEO & Director
- JAJason A. KeyesCFO & Executive VP
- GOGeoff OxnardChief Medical Officer & Executive VP
- VLVincent LiptakGeneral Counsel & Executive VP
- SKSheila K. GujrathiLead Independent Director
- JPJohn P. SchmidIndependent Director
